Statens Serum Institut
🇩🇰Denmark
Clinical Trials
40
Active:8
Completed:30
Trial Phases
5 Phases
Phase 1:15
Phase 2:5
Phase 3:7
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials
Phase 1
15 (50.0%)Phase 3
7 (23.3%)Phase 2
5 (16.7%)Phase 4
2 (6.7%)Not Applicable
1 (3.3%)First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b
Phase 1
Recruiting
- Conditions
- Healthy
- Interventions
- Biological: H107e/CAF®10b - full adjuvant doseBiological: H107eBiological: CAF®10bBiological: H107e/CAF®10bBiological: H107e/CAF®10b - low adjuvant doseBiological: i.m. placeboBiological: Full dose intranasal H107eBiological: Low dose intranasal H107eBiological: i.d. placeboBiological: Intranasal H107e
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 140
- Registration Number
- NCT06050356
- Locations
- 🇿🇦
Aurum Institute, Pretoria, Gauteng, South Africa
Safety and Immunogenicity of a Chlamydia Vaccine CTH522
Phase 1
Completed
- Conditions
- Trachoma
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 65
- Registration Number
- NCT03926728
- Locations
- 🇬🇧
NIHR Imperial Center for Translational and Experimental Medicine, London, United Kingdom
Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months
Phase 3
Completed
- Conditions
- Poliomyelitis
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 666
- Registration Number
- NCT03671616
- Locations
- 🇵🇦
Cevaxin, Panama City, Panama
Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months
Phase 3
Completed
- Conditions
- Poliomyelitis
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 1002
- Registration Number
- NCT03032419
- Locations
- 🇵🇭
5 sites in Philippines, Manila, Philippines
Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age
Phase 3
Completed
- Conditions
- Poliomyelitis
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 800
- Registration Number
- NCT03025750
- Locations
- 🇵🇦
Cevaxin, Panama City, Panama
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
No news found